Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer

Breast

Volumn 18, Issue SUPPL. 2, 2009, Pages

  Chlebowski, Rowan ^a   Cuzick, Jack ^b   Amakye, Dereck ^c   Bauerfeind, Ingo ^d   Buzdar, Aman ^e   Chia, Stephen ^f   Cutuli, Bruno ^g   Linforth, Rick ^h   Maass, Nicolaì ⁱ   Noguchi, Shinzaburo ^j   Robidoux, André ^k   Verma, Sunil ^l   Hadji, Peyman ^m  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d Klinikum Landshut   (Germany)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g Polyclinique de Courlancy   (France)

^h ST LUKE S HOSPITAL   (United Kingdom)

ⁱ RWTH AACHEN UNIVERSITY   (Germany)

^j OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k UNIVERSITÉ DE MONTRÉAL   (Canada)

^l UNIVERSITY OF TORONTO   (Canada)

^m PHILIPPS UNIVERSITY MARBURG   (Germany)

more..

Author keywords

Adjuvant therapy; Aromatase inhibitor; Breast cancer; Duration of treatment; Endocrine therapy

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; DENOSUMAB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TAMOXIFEN; VITAMIN D; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ARTERY THROMBOSIS; ARTHRALGIA; ARTICLE; AXILLARY LYMPH NODE; BONE DENSITY; BONE PAIN; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE FREE SURVIVAL; DOCTOR PATIENT RELATION; DOSAGE SCHEDULE COMPARISON; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FRACTURE; GENE OVEREXPRESSION; HUMAN; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; LUNG EMBOLISM; LYMPH NODE METASTASIS; MEMORY DISORDER; MYALGIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECURRENCE RISK; RISK REDUCTION; SIDE EFFECT; STROKE; TREATMENT DURATION; TREATMENT RESPONSE; VEIN THROMBOSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NITRILES; POSTMENOPAUSE; RECURRENCE; SURVIVAL ANALYSIS; TAMOXIFEN; TRIAZOLES; WOMEN'S HEALTH;

EID: 68949172393     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(09)70002-5     Document Type: Article

References (92)

1. The ATAC Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 (2008) 45-53
2. Mouridsen H.T., Giobbie-Hurder A., Mauriac L., et al. BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Cancer Res 69 Suppl 2 (2009) 13 (abstract).
3. Yang H.C., Thornton L.M., Shapiro C.L., and Andersen B.L. Surviving recurrence: psychological and quality-of-life recovery. Cancer 112 (2008) 1178-1187
4. Northouse L.L., Mood D., Kershaw T., et al. Quality of life of women with recurrent breast cancer and their family members. J Clin Oncol 20 (2002) 4050-4064
5. Sarenmalm E.K., Ohlen J., Jonsson T., and Gaston-Johansson F. Coping with recurrent breast cancer: predictors of distressing symptoms and health-related quality of life. J Pain Symptom Manage 34 (2007) 24-39
6. Lamerato L., Havstad S., Gandhi S., Jones D., and Nathanson D. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer 106 (2006) 1875-1882
7. Haffty B.G., Reiss M., Beinfield M., et al. Ipsilateral breast tumor recurrence as a predictor of distant disease: implications for systemic therapy at the time of local relapse. J Clin Oncol 14 (1996) 52-57
8. Komoike Y., Akiyama F., Iino Y., et al. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer 106 (2006) 35-41
9. Le M.G., Arriagada R., Spielmann M., Guinebretiere J.M., and Rochard F. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer 94 (2002) 2813-2820
10. Cuzick J. Primary endpoints for randomised trials of cancer therapy. Lancet 371 (2008) 2156-2158
11. Coates A.S., Keshaviah A., Thürlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
12. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
13. Ingle J, Dowsett M, Cuzick J, Davies C; for the Aromatase Inhibitors Overview Group (AIOG). Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. Available at http://sabcs08.m2usa.com/sabcsol.html. Last updated 2008. Accessed 18 May 2009.
14. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88 (1996) 1529-1542
15. Giordano S.H., Buzdar A.U., Smith T.L., et al. Is breast cancer survival improving?. Cancer 100 (2004) 44-52
16. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 (2007) 559-570
17. Hanrahan E.O., Gonzalez-Angulo A.M., Giordano S.H., et al. Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 25 (2007) 4952-4960
18. Chapman J.A., Meng D., Shepherd L., et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 100 (2008) 252-260
19. Kaufmann M., Jonat W., Hilfrich J., et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after 2 years of treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 Study. J Clin Oncol 25 (2007) 2664-2670
20. Joerger M., and Thürlimann B. Update of the BIG 1-98 Trial: Where do we stand?. Breast 18 Suppl 3 (2009) in press.
21. Buzdar A.U., Cuzick J., Baum M., and on behalf of the ATAC Trialists' Group. Is overall survival an appropriate endpoint in studies of early breast cancer? Data from the ATAC study at 100 months' median follow-up. J Clin Oncol (Meeting Abstracts) 26 May 20 Suppl (2008) 552 (abstract).
22. Peto R, Davies C; on behalf of the ATLAS Collaboration. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11500 women - preliminary results. Abstract presented at the 30th Annual San Antonio Breast Cancer Symposium, 2007.
23. Jakesz R., Gnant M., Griel R., et al. Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. Available at http://sabcs08.m2usa.com/sabcsol.html Last updated 2008. Accessed 7 July 2009.
24. Dowsett M., Cuzick J., Wale C., et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23 (2005) 7512-7517
25. Dowsett M., Allred C., Knox J., et al. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26 (2008) 1059-1065
26. Rasmussen B.B., Regan M.M., Lykkesfeldt A.E., et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 9 (2008) 23-28
27. Ingle J.N. Pharmacogenomics of tamoxifen and aromatase inhibitors. Cancer 112 (2008) 695-699
28. Goetz M.P., Knox S.K., Suman V.J., et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101 (2007) 113-121
29. Jin Y., Desta Z., Stearns V., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97 (2005) 30-39
30. Schroth W., Antoniadou L., Fritz P., et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25 (2007) 5187-5193
31. Goetz M., Ames M., Gnant M., et al. Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial. Available at http://sabcs08.m2usa.com/sabcsol.html Last updated 2008. Accessed 7 July 2009.
32. Wegman P., Elingarami S., Carstensen J., et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 9 (2007) R7
33. Nowell S.A., Ahn J., Rae J.M., et al. Association of genetic variation in tamoxifenmetabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91 (2005) 249-258
34. Abraham JE, Maranian MJ, Driver KE, et al. CYP2D6 variants and their association with overall survival in breast cancer. Poster presented at the San Antonio Breast Cancer Symposium, 2008.
35. Cuzick J., Sestak I., Cella D., and Fallowfield L. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9 (2008) 1143-1148
36. Fabian C.J., and Kimler B.F. Use of biomarkers for breast cancer risk assessment and prevention. J Steroid Biochem Mol Biol 106 (2007) 31-39
37. Visvanathan K., Chlebowski R.T., Hurley P., et al. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27 (2009) 3235-3258
38. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
39. Saadat M., Truong P.T., Kader H.A., et al. Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer: comparison of cohorts treated with and without tamoxifen. Cancer 110 (2007) 31-37
40. Bergman L., Beelen M.L., Gallee M.P., et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group [Assessment of Liver and Endometrial Cancer Risk following Tamoxifen]. Lancet 356 (2000) 881-887
41. Duffy S.R., Distler W., Howell A., Cuzick J., and Baum M. A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. Am J Obstet Gynecol 200 (2009) 80-87
42. Jenkins V.A., Ambroisine L.M., Atkins L., et al. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncol 9 (2008) 953-961
43. Schilder C.M., Eggens P.C., Seynaeve C., et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 48 (2009) 76-85
44. Ribi K.E., Phillips K.A., Sun Z., et al. Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen in the Breast International Group (BIG) 1-98 trial. J Clin Oncol 27 Suppl (2009) 15S 510 (abstract).
45. Hermelink K., Henschel V., Untch M., et al. Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer 113 (2008) 2431-2439
46. Hadji P. Reducing the risk of bone loss associated with breast cancer treatment. Breast 16 Suppl 3 (2007) S10-S15
47. Jakesz R., Gnant M., Greil R., et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5-year-analysis of ABCSG Trial 8. Breast Cancer Res Treat 94 Suppl 1 (2005) S10
48. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
49. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
50. Hadji P., Body J.J., Aapro M.S., et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 19 (2008) 1407-1416
51. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 (2003) 4042-4057
52. Reid D.M., Doughty J., Eastell R., et al. Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treat Rev 34 (2008) S3-18
53. Van Poznak C, Hannon R, Clack G, et al. Managing cancer treatment-induced bone loss: 24-month results from the study of anastrozole with the bisphosphonate risedronate (SABRE). Poster presented at the San Antonio Breast Cancer Symposium, 2008.
54. The ATAC Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7 (2006) 633-643
55. Cauley J.A., Wu L., Wampler N.S., et al. Clinical risk factors for fractures in multi-ethnic women: the Women's Health Initiative. J Bone Miner Res 22 (2007) 1816-1826
56. Siris E.S., Brenneman S.K., Barrett-Connor E., et al. The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50-99: results from the National Osteoporosis Risk Assessment (NORA). Osteoporos Int 17 (2006) 565-574
57. Eastell R., Adams J.E., Coleman R.E., et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 26 (2008) 1051-1057
58. Coleman R.E., and on behalf of the ATAC Trialists' Group. Long-term effects of anastrozole on bone mineral density: Seven-year results from the ATAC trial. J Clin Oncol 26 (2008)
59. Brufsky A., Bundred N., Coleman R., et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13 (2008) 503-514
60. Aapro M. Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program. Breast 15 Suppl 1 (2006) S30-S40
61. Ellis G.K., Bone H.G., Chlebowski R., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26 (2008) 4875-4882
62. Cohen A., Fleischer J.B., Johnson M.K., et al. Prevention of bone loss after withdrawal of tamoxifen. Endocr Pract 14 (2008) 162-167
63. Coleman R.E., Banks L.M., Girgis S.I., et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8 (2007) 119-127
64. Hadji P., Ziller M., Kieback D.G., et al. The effect of exemestane or tamoxifen on markers of bone turnover: results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial. Breast 18 (2009) 159-164
65. Crew K.D., Greenlee H., Capodice J., et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25 (2007) 3877-3883
66. Presant C.A., Kelly C., Bosserman L., et al. Aromatase inhibitor (AI)-associated arthralgia (A) and bone pain (BP): Frequency and characterization in clinical practice. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 24 Suppl (2006) 18S 6137 (abstract).
67. Sestak I., Cuzick J., Sapunar F., et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9 (2008) 866-872
68. Morales L., Pans S., Verschueren K., et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J-Clin Oncol 26 (2008) 3147-3152
69. Coleman R.E., Bolten W.W., Lansdown M., et al. Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations. Cancer Treat Rev 34 (2008) 275-282
70. Chlebowski R.T., Johnson K.C., Kooperberg C., et al. The Women's Health Initiative randomized trial of calcium plus vitamin D: breast cancer and arthralgia effects. Proc Am Soc Clin Oncol 25 (2006) 6 (ASCO plenary presentation).
71. Renshaw L., McHugh M., Williams L., et al. Comparison of joint symptoms as reported by patients in a randomized adjuvant trial of anastrozole and letrozole. Breast Cancer Res Treat 106 (2007) S108
72. Briot K, Bastit L, Rotarsky M, et al. Aromatase inhibitors-induced joint pain: effect of the switch of aromatase inhibitors. Poster presented at the San Antonio Breast Cancer Symposium 2008.
73. Chlebowski R.T. Aromatase associated arthralgias. J Clin Oncol (2009) in press.
74. Jonat W., Gnant M., Boccardo F., et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 7 (2006) 991-996
75. Mamounas E.P., Jeong J.H., Wickerham D.L., et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-totreat. analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol 26 (2008) 1965-1971
76. Jakesz R., Samonigg H., Greil R., et al. Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol (Meeting Abstracts) 23 (2005) 10s 527 (abstract).
77. Gray R.G., Rea D.W., Handley K., et al. aTTom (adjuvant Tamoxifen - To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer - Preliminary results. J Clin Oncol 26 May 20 Suppl (2008) 513 (abstract).
78. Miller K.D., and Muss H.B. Management of breast cancer in the adjuvant and metastatic settings. Neil Love, Patterns of Care in Medical Oncology (Research to Practice) 5 (2008) 1-32
79. Citron M., Amakye D., and Chlebowski R. A survey of oncologists on the duration of adjuvant aromatase-inhibitor therapy - factors that influence treatment decisions in early breast cancer. Poster presented at the St Gallen 11th International Conference. Breast 18 Suppl 1 (2009) S52 abstract 0133.
80. Osterberg M.D., and Blaschke T. Adherence to medication. N Engl J Med 353 (2005) 487-497
81. Berg J.S., Dischler J., Wagner D.J., Raia J.J., and Palmer-Shevlin N. Medication compliance: a healthcare problem. Ann Pharmacother 27 (1993) S1-24
82. Hadji P. Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr Relat Cancer 15 (2008) 73-90
83. Chlebowski R., and Geller M.L. Adherence to endocrine therapy for breast cancer. Oncology 71 (2006) 1-9
84. Partridge A.H., Wang P.S., Winer E.P., and Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21 (2003) 602-606
85. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
86. Owusu C., Buist D.S., Field T.S., et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26 (2008) 549-555
87. Ziller V., Kalder M., Albert U.S., et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20 (2009) 431-436
88. Fink A.K., Gurwitz J., Rakowski W., Guadagnoli E., and Silliman R.A. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22 (2004) 3309-3315
89. Partridge A.H., LaFountain A., Mayer E., et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26 (2008) 556-562
90. Hadji P., Jackisch C., Blettner M., et al. Non-compliance in der adjuvanten, endokrinen Therapie des Mammakarzinoms. Geburtshilfe Frauenheilkd 67 (2007) 493-497
91. Friedman L, Schluchter M, Silverman P, et al. Adherence to endocrine therapy in women with breast cancer in a clinical practice setting. Poster presented at the San Antonio Breast Cancer Symposium, 2008.
92. Neven P., Serin D., Separovic R., Ozaslan C., and Tanner M. CARIATIDE study: Evaluation of the impact of educational material on the compliance and persistence rates to adjuvant aromatase inhibitor (AI) medication for postmenopausal women with hormone sensitive early breast cancer. Breast 18 Suppl 1 (2009) S52